Vincent graduated with a MSc degree in Medical Biology from the University of Amsterdam, where he also obtained a PhD in Biochemistry. His doctoral research focused on the phospholipid flippase ATP8B1 and its role in intracellular trafficking. This work resulted in three first-authored experimental publications in highly-ranked scientific journals.
Following this Vincent continued to work in academia as a post-doctoral researcher in the Academic Medical Center in Amsterdam. Using direct input from the pharmaceutical industry he developed and studied several cell culture systems that can act as models for drug metabolism and toxicity testing. He also became the main inventor on a patent application for a new improved liver cell line with potential use in a bio-artificial liver system.
Vincent went on to work as an analyst in the Healthcare team of M Ventures, the corporate venture capital arm of Merck KGaA, where he performed due diligence on technical, commercial and patented features of new investment proposals in the fields of (immuno-)oncology and immunology.
Prior to joining HGF, Vincent worked in the technology transfer office of the University of Leiden, specifically at the Leiden University Medical Center. Here, his roles included scouting for new (patentable) inventions, IP management, business development, advising on start-ups and investments, licencing and research agreements. During this time he came into contact with many cutting-edge technologies in the field of medical devices, diagnostic methods, software applications, antibodies, and cancer neoepitopes.
At HGF Vincent has gained ample experience with FTO analyses and drafting and prosecuting patents.
A patent is a legal right that enables the patent holder to prevent others from making and using their invention in the country where the patent is granted. To many …Read article
Order of the classifications listed on the front of a patent and why it matters? On 1 June 2023, ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE lodged a statement of revocation of …Read article
HGF is pleased to invite you to our upcoming German-language webinar in cooperation with the BVIZ on “In- and Out-licensing of Technologies” on 16th of November 2023. The webinar will …Event details
The advent of commercial launch capabilities has opened up space as a unique frontier for innovation. However, in space, any acts of patent infringement almost always go unseen. Thus, it’s …Read article
Any communications sent from the EPO on or after 1 November 2023 will no longer have the “ten day rule” applied to them. This means that communications are deemed to …Read article
HGF is pleased to invite you to our upcoming German-language seminar on “In- and Out-licensing of Technologies” in Salzburg and Dresden. The seminar will offer you the opportunity to gain …Event details
Bioforward, OBN’s ‘Roadmap for Growth’ Life Sciences event is set to take place at The King’s Centre in Oxford on Tuesday 26th September 2023. This event is designed to provide the support, skills, know-how …Event details
The integration of artificial intelligence (AI) into healthcare has ushered in a new era of personalised medicine, promising more effective and tailored treatments for patients. Traditional medical approaches often adopt …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.